Pharmaceutical pricing: Early access, the cancer drugs fund and the role of NICE

The real problem that NHS patients face in accessing new medicines is the discrepancy between the price charged and how much the NHS can afford to pay for the benefits they offer. Read more

Other Policy & Research Briefing papers can be found here